Stoke Therapeutics (STOK) EBIT Margin (2022 - 2026)
Stoke Therapeutics' (STOK) quarterly EBIT Margin came in at 857.57% in Q1 2026, down 92772.0% year-on-year from N/an in Q1 2025, and up 80.43% quarter-over-quarter from 4382.24% in Q4 2025.
Stoke Therapeutics (STOK) EBIT Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBIT Margin history runs 5 years deep, the most recent figure standing at 857.57% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 92772.0% year-over-year to 857.57% in Q1 2026; TTM through Mar 2026 was 577.46%, a 59749.0% decrease from a year earlier, with the FY2025 full-year figure at 11.16%, up 26615.0% from the prior year.
- EBIT Margin grew to 857.57% in Q1 2026 per STOK's latest filing, from 4382.24% in the prior quarter.
- Across five years, EBIT Margin topped out at 70.15% in Q1 2025 and bottomed at 4382.24% in Q4 2025.
- The 5-year median for EBIT Margin is 781.12% (2022), against an average of 870.53%.
- Across the five-year window, EBIT Margin surged 99551 bps in 2024 and sank 432187 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 831.58% in 2022, then declined by 27 bps to 1055.89% in 2023, then surged by 94 bps to 60.37% in 2024, then tumbled by 7158 bps to 4382.24% in 2025, then jumped by 80 bps to 857.57% in 2026.
- Per Business Quant, the three latest STOK EBIT Margin figures stand at 857.57% (Q1 2026), 4382.24% (Q4 2025), and 405.3% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -857.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -857.57% |
| Dec 31, 2025 | -4,382.24% |
| Sep 30, 2025 | -405.30% |
| Jun 30, 2025 | -197.58% |
| Mar 31, 2025 | 70.15% |
| Dec 31, 2024 | -60.37% |
| Sep 30, 2024 | -613.06% |
| Jun 30, 2024 | -607.37% |
| Mar 31, 2024 | -672.96% |
| Dec 31, 2023 | -1,055.89% |
| Sep 30, 2023 | -823.28% |
| Jun 30, 2023 | -1,340.67% |
| Mar 31, 2023 | -479.23% |
| Dec 31, 2022 | -831.58% |
| Sep 30, 2022 | -934.53% |
| Jun 30, 2022 | -781.12% |
| Mar 31, 2022 | -826.50% |